GlassScriptPhysician profile
Barry Pearlman
NPI 1326057746
$1,414.40
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $421 · 2020: $221 · 2021: $574 · 2022: $137 · 2023: $61.28.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $61.28.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $61.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $384.54 | 2019-2022 | |
| Ferring Pharmaceuticals INC. | $274.69 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $238.51 | 2019-2022 | |
| Glaxosmithkline, LLC. | $71.91 | 2019-2021 | |
| Abbvie INC. | $50.08 | 2021-2023 | |
| Lilly USA, LLC | $43.44 | 2021 | |
| Bausch Health US, LLC | $43.38 | 2021-2023 | Aplenzin |
| Actelion Pharmaceuticals US, INC. | $41.51 | 2021-2022 | |
| Pulmonx Corporation | $38.64 | 2022 | |
| Paratek Pharmaceuticals, INC. | $35.24 | 2020-2022 | |
| Alexion Pharmaceuticals, INC. | $33.96 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.49 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $24.35 | 2021 | |
| Grifols USA, LLC | $21.79 | 2021 | |
| Braintree Laboratories, INC. | $20.35 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $19.89 | 2022 | |
| Idorsia Pharmaceuticals US INC | $19.17 | 2023 | Quviviq |
| Eisai INC. | $13.00 | 2021 | |
| Abbott Laboratories | $12.46 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barry Pearlman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.